RU2007138584A - Соединения, обладающие активностью для коррекции процессинга мутантного cftr, и их применение - Google Patents
Соединения, обладающие активностью для коррекции процессинга мутантного cftr, и их применение Download PDFInfo
- Publication number
- RU2007138584A RU2007138584A RU2007138584/04A RU2007138584A RU2007138584A RU 2007138584 A RU2007138584 A RU 2007138584A RU 2007138584/04 A RU2007138584/04 A RU 2007138584/04A RU 2007138584 A RU2007138584 A RU 2007138584A RU 2007138584 A RU2007138584 A RU 2007138584A
- Authority
- RU
- Russia
- Prior art keywords
- group
- pharmaceutical composition
- pharmaceutically acceptable
- composition according
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66350105P | 2005-03-18 | 2005-03-18 | |
US60/663,501 | 2005-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2007138584A true RU2007138584A (ru) | 2009-04-27 |
Family
ID=37024308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007138584/04A RU2007138584A (ru) | 2005-03-18 | 2006-03-08 | Соединения, обладающие активностью для коррекции процессинга мутантного cftr, и их применение |
Country Status (12)
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
PT2489659T (pt) | 2004-06-24 | 2018-03-07 | Vertex Pharma | Moduladores de transportadores de cassete de ligação a atp |
CA2635214A1 (en) * | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
BRPI0620960A2 (pt) | 2005-12-28 | 2011-11-29 | Vertex Pharmaceuticals Incorporated | formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-didro-4- oxiquinolina-3- carboxamida |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
PT2007756E (pt) | 2006-04-07 | 2015-11-02 | Vertex Pharma | Modeladores de transportadores de cassetes de ligação de atp |
CN101096363B (zh) * | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途 |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
KR20100016073A (ko) | 2007-04-02 | 2010-02-12 | 인스티튜트 포 원월드 헬스 | Cftr 억제제 화합물 및 이의 용도 |
EA200901489A1 (ru) | 2007-05-07 | 2010-04-30 | Новартис Аг | Органические соединения |
WO2009023509A2 (en) * | 2007-08-09 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Therapeutic combinations useful in treating cftr related diseases |
SI2195312T1 (sl) | 2007-10-09 | 2013-01-31 | Merck Patent Gmbh | Derivati piridina, uporabni kot aktivatorji glukokinaze |
US8389736B2 (en) * | 2007-10-16 | 2013-03-05 | The Regents Of The University Of California | Compounds having activity in correcting mutant-CFTR processing and uses thereof |
PL2578571T3 (pl) | 2007-11-16 | 2016-03-31 | Vertex Pharma | Modulatory izochinolinowe transporterów zawierających kasetę wiążącą ATP |
SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
AU2008334629B2 (en) | 2007-12-10 | 2012-04-12 | Novartis Ag | Organic compounds |
DK2615085T3 (en) | 2008-03-31 | 2015-10-05 | Vertex Pharma | Pyridyl derivatives as CFTR modulators |
EP2278879B1 (en) * | 2008-04-21 | 2016-06-15 | PATH Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2009131952A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising thiazole derivatives |
WO2009131951A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
KR20110040818A (ko) | 2008-06-10 | 2011-04-20 | 노파르티스 아게 | 상피 나트륨 채널 차단제로서의 피라진 유도체 |
MX2011008131A (es) * | 2009-02-02 | 2012-01-20 | Chromocell Corp | Lineas celulares que expresan cftr y los métodos para utilizarlas. |
KR101955863B1 (ko) | 2009-03-20 | 2019-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
US20110098311A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorported | Compositions for treatment of cystic fibrosis and other chronic diseases |
CN109081804B (zh) * | 2010-03-25 | 2021-12-10 | 弗特克斯药品有限公司 | 环丙烷甲酰胺的固体形式 |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
NZ708598A (en) | 2010-04-07 | 2017-05-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d](1,3)dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
SI2555754T1 (sl) | 2010-04-07 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Trdne farmacevtske oblike 3-(6-(1-(2,2-difluoro-benzo(d)(1,3)dioksol-5- il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline |
EP3381899B1 (en) | 2010-04-22 | 2021-01-06 | Vertex Pharmaceuticals Incorporated | Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
JP2013536231A (ja) | 2010-08-23 | 2013-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | (r)−1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)−n−(1−(2,3−ジヒドロキシプロピル)−6−フルオロ−2−(1−ヒドロキシ−2−メチルプロパン−2−イル)−1h−インドール−5−イル)シクロプロパンカルボキサミドを含む医薬組成物およびその投与 |
CN104478800A (zh) | 2010-09-14 | 2015-04-01 | 波兰科学院生物化学与生物物理研究所 | 作为突变cftr蛋白的调节剂的化合物及其在治疗与cftr蛋白失常相关的疾病中的用途 |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
WO2012166654A1 (en) * | 2011-05-27 | 2012-12-06 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
CA2754237A1 (en) | 2011-05-27 | 2012-11-27 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
JP6182136B2 (ja) | 2011-06-29 | 2017-08-16 | ヤンセン ファーマシューティカ エヌ.ベー. | マトリックスメタロプロテアーゼのアロステリックなプロセシング阻害因子を設計、選択及び/又は最適化するための方法 |
EP2726073A1 (en) * | 2011-06-29 | 2014-05-07 | Janssen Pharmaceutica, N.V. | Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases |
CA2840202A1 (en) | 2011-06-29 | 2013-01-03 | Janssen Pharmaceutica Nv | Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor |
IN2014KN00885A (US20080318984A1-20081225-C00062.png) | 2011-11-08 | 2015-10-02 | Vertex Pharma | |
SI2806859T1 (sl) | 2012-01-25 | 2019-11-29 | Vertex Pharma | Formulacije 3-(6-(1-(2.2-difluorobenzo(d)(1,3)dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline |
IL311180A (en) | 2012-02-27 | 2024-04-01 | Vertex Pharma | Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
EP2914248B2 (en) | 2012-11-02 | 2023-10-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
GB201405991D0 (en) * | 2014-04-03 | 2014-05-21 | Cambridge Entpr Ltd | Novel compounds |
HRP20230709T1 (hr) | 2014-04-15 | 2023-10-13 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci za liječenje bolesti povezanih s regulatorom provodljivosti transmembrane cistične fibroze |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
JP6896619B2 (ja) | 2014-10-06 | 2021-06-30 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーター |
RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
WO2016087665A2 (en) | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
WO2016123253A1 (en) * | 2015-01-27 | 2016-08-04 | Rutgers, The State University Of New Jersey | Hydrazne derivatives for the treatment of cancer |
US10729671B2 (en) | 2015-01-27 | 2020-08-04 | Rutgers, The State University Of New Jersey | Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer |
US10604480B2 (en) | 2015-01-27 | 2020-03-31 | Rutgers, The State University Of New Jersey | (Thio, oxo, and seleno) semicarbazone derivatives and their use for treating cancer |
US10221133B2 (en) | 2015-01-27 | 2019-03-05 | Rutgers, The State University Of New Jersey | (Thio, oxo, and seleno) semicarbazone complexes with zinc and their use for treating cancer |
ITUB20153714A1 (it) * | 2015-09-18 | 2017-03-18 | Luigina Romani | Timosina alfa 1 per l?uso nel trattamento della fibrosi cistica. |
WO2016129005A1 (en) * | 2015-02-09 | 2016-08-18 | Luigina Romani | Thymosin alpha 1 for use in treatment of cystic fibrosis |
US20170100374A1 (en) * | 2015-10-09 | 2017-04-13 | AbbVie S.à.r.l. | Potentiator-corrector combinations useful in the treatment of cystic fibrosis |
CA3088229A1 (en) | 2018-01-11 | 2019-07-18 | Genethon | Combination treatment of sarcoglycanopathies |
MX2021002653A (es) | 2018-09-09 | 2021-09-23 | Qanatpharma Ag | Uso de moduladores de cftr para el tratamiento de condiciones cerebrovasculares. |
KR102399037B1 (ko) * | 2020-01-06 | 2022-05-17 | 성균관대학교산학협력단 | 아민화된 아진의 신규한 제조방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0069154B1 (en) * | 1981-01-13 | 1986-10-15 | Mitsui Toatsu Kagaku Kabushiki Kaisha | Novel thiazole compounds, process for their preparation, and medicinal composition containing same |
JPS649935A (en) * | 1987-06-30 | 1989-01-13 | Kyowa Hakko Kogyo Kk | Remedy for hepatopathy |
EP0519449A1 (en) * | 1991-06-21 | 1992-12-23 | Boehringer Mannheim Italia S.P.A. | 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract |
US6262096B1 (en) * | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
EP1353676A4 (en) * | 2000-12-29 | 2006-05-31 | Alteon Inc | METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS |
HN2002000156A (es) * | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
SE0201837D0 (sv) | 2002-06-14 | 2002-06-14 | Astrazeneca Ab | Chemical compounds |
US7329682B2 (en) * | 2003-04-03 | 2008-02-12 | Ewha University-Industry Collaboration Foundation | Method for inhibiting 5-lipoxygenase using a benzoxazole derivative |
WO2004098510A2 (en) * | 2003-04-30 | 2004-11-18 | Beth Israel Deaconess Medical Center | Cystic fibrosis therapy |
WO2004110352A2 (en) | 2003-05-16 | 2004-12-23 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
-
2006
- 2006-03-08 WO PCT/US2006/008267 patent/WO2006101740A2/en active Application Filing
- 2006-03-08 MX MX2007011512A patent/MX2007011512A/es not_active Application Discontinuation
- 2006-03-08 JP JP2008501913A patent/JP2008538107A/ja not_active Withdrawn
- 2006-03-08 KR KR1020077024001A patent/KR20070114820A/ko not_active Application Discontinuation
- 2006-03-08 RU RU2007138584/04A patent/RU2007138584A/ru not_active Application Discontinuation
- 2006-03-08 BR BRPI0608453-2A patent/BRPI0608453A2/pt not_active Application Discontinuation
- 2006-03-08 AU AU2006227833A patent/AU2006227833A1/en not_active Abandoned
- 2006-03-08 CN CNA2006800150356A patent/CN101605543A/zh active Pending
- 2006-03-08 CA CA002600869A patent/CA2600869A1/en not_active Abandoned
- 2006-03-08 US US11/908,591 patent/US8143295B2/en active Active
- 2006-03-08 EP EP06737438A patent/EP1863522A4/en not_active Withdrawn
-
2007
- 2007-09-17 IL IL185999A patent/IL185999A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006101740A2 (en) | 2006-09-28 |
CN101605543A (zh) | 2009-12-16 |
IL185999A0 (en) | 2008-08-07 |
KR20070114820A (ko) | 2007-12-04 |
MX2007011512A (es) | 2007-12-07 |
EP1863522A4 (en) | 2010-11-10 |
EP1863522A2 (en) | 2007-12-12 |
JP2008538107A (ja) | 2008-10-09 |
US20080318984A1 (en) | 2008-12-25 |
BRPI0608453A2 (pt) | 2009-12-29 |
WO2006101740A3 (en) | 2009-06-04 |
US8143295B2 (en) | 2012-03-27 |
AU2006227833A1 (en) | 2006-09-28 |
CA2600869A1 (en) | 2006-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007138584A (ru) | Соединения, обладающие активностью для коррекции процессинга мутантного cftr, и их применение | |
NZ515282A (en) | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions | |
EA200000993A1 (ru) | Тризамещенные производные 1,3,5-триазина для лечения вич-инфекционных заболеваний | |
NO20051754L (no) | Quinolylpropylpiperidinderivater, fremgangsmate for fremstilling derav og mellomprodukter og preparater inneholdende slike derivater | |
BR0214876A (pt) | Formas de sal de e-2-metóxi-n-(3-(4-(3-metil-piridin-3-ilóxi)-fenilamino)qui nazolin-6-il)-alil)-acetamida, suas preparações e uso dos mesmos contra o câncer | |
EE04911B1 (et) | Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks | |
HRP20141184T1 (en) | Novel method for preventing or treating m. tuberculosis infection | |
EA200400305A1 (ru) | 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность | |
NO20060706L (no) | Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease | |
EA200201263A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ | |
PE20060243A1 (es) | Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina | |
CA2398794A1 (en) | 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists | |
RU2006130686A (ru) | Новые пиперидины в качестве модуляторов хемокинов (ccr) | |
TW200619195A (en) | Phenylpyrrolidine dopamine D3 receptor antagonists | |
SE9904413D0 (sv) | Comminuted form | |
DE59909210D1 (de) | Urokinase-Inhibitoren | |
TW200744589A (en) | Pharmaceutical composition | |
NO20065873L (no) | 3-(4-(2-dihydroisoksazol-3-ylpyridin-5-yl)fenyl)-5-triazol-1-ylmetyloksoazolidin-2-on derivater som MAO inhibitorer i behandlingen av bakterielle infeksjoner | |
NO20065902L (no) | 3-{4-(pyridin-3-yl)fenyl}-5-(1H-,1,2,3-triazol-1-ylmetyl)-1,3-oksazolidin-2-oner som antibakterielle midler | |
EA200500095A1 (ru) | Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств | |
ATE409187T1 (de) | N-(substituierte benzyl)-8-hydroxy-1,6- naphthyridin-7- carbonsäureamide als hiv- integrase-hemmer | |
DE60035429D1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
NO983178L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasaytisk preparat for behandling eller profylakse av menopausesymptomer | |
RU2004107847A (ru) | Изоксазолпиридиноны и их применение в лечении болезни паркинсона | |
RU2008144660A (ru) | Лизобактинамиды |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20090423 |